株探米国株
英語
エドガーで原本を確認する
6-K 1 ea0237289-6k_moolec.htm REPORT OF FOREIGN PRIVATE ISSUER

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rules 13a-16 or 15d-16 under

the Securities Exchange Act of 1934

 

For the month of April 2025

 

Commission File Number: 001-41586

 

MOOLEC SCIENCE SA

(Exact name of Registrant as Specified in Its Charter)

 

17, Boulevard F. W. Raiffeisen

L-2411 Luxembourg,

Grand Duchy of Luxembourg

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F  ☒           Form 40-F  ☐

 

 

 


 

EXPLANATORY NOTE

 

Attached hereto as Exhibit 99.1 is the Convening Notice for the Extraordinary General Meeting of the shareholders of Moolec SA (the “Company”) to be held on April 22, 2025, at 1:00 p.m. Central European Time) at 35, avenue J. F. Kennedy, L-1855 Luxembourg, Grand Duchy of Luxembourg. Matters submitted to the Extraordinary General Meeting include the approval of the transfer of the central administration (administration centrale) and registered office (siège social) of the Company from the Grand Duchy of Luxembourg to the Cayman Islands, and to set the registered office of the Company at c/o Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman KY1-9009, Cayman Islands, with effect as from the Effective Date (as defined in the convening notice), to acknowledge the Migration (as defined in the convening notice) and to approve the Share Capital Reduction (as defined in the convening notice) of the Company so as to reduce the share capital pursuant to the Consolidation Ratio (as defined in the convening notice), which will be set between 2:1 and 10:1.

 

On April 6, 2025, the Company received a letter from Theo SCSp and Union Group Ventures Ltd., acting as shareholders of the Company, holding together more than 10% of the share capital. The letter requested that, in accordance with Article 450-8 of Luxembourg law dated August 10, 1915, on commercial companies, as amended, three agenda items be added to the agenda of the EGM. Specifically, Theo SCSp and Union Group Ventures Ltd. requested the general meeting of shareholders to resolve upon the appointment of Diego Nicolás Marcos and Oscar Alejandro León Bentancor as directors of the Company, each with immediate effect, to last until the general meeting that will approve the accounts for the period ending on June 30, 2025. Furthermore, subject to the approval of Messrs. Marcos and Bentancor’s appointments, it should be acknowledged that as of the Effective Date, the composition of the board of directors will remain unchanged from its state as of the date of the EGM.

 

The Luxembourg-law governed Articles of Association to be adopted by the Company at the Extraordinary General Meeting of shareholders scheduled for April 22, 2024, subject to the approval of the first resolution, are substantially similar to the Articles of Association in effect before the Extraordinary General Meeting held on December 27, 2024 (the “2024 EGM”). The Cayman-law Articles of Association to be adopted by the Company at the EGM, subject to the approval of the ninth resolution, are substantially similar to those adopted at the 2024 EGM, except that paragraph 8 of the Memorandum of Association will be updated to reflect the Company’s share capital following the implementation of the share consolidation described in fourth, fifth and sixth resolutions.

 

This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

 

1


 

Exhibit List

 

Exhibit No.   Description
99.1   Convening Notice for the Extraordinary General Meeting of Shareholders of Moolec Science SA
99.2   Notification related to the addition of agenda items to the General Meeting to be held on April 22, 2025

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  MOOLEC SCIENCE SA
  (Registrant)
     
Dated: April 7, 2025 By: /s/ Gastón Paladini
  Name:  Gastón Paladini
  Title: Chief Executive Officer

 

 

3

 

 

EX-99.1 2 ea023728901ex99-1_moolec.htm CONVENING NOTICE FOR THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF MOOLEC SCIENCE SA

Exhibit 99.1

 

 

 

Moolec Science SA 

Société anonyme

17, boulevard F.W. Raiffeisen, L-2411 Luxembourg

Grand Duchy of Luxembourg

R.C.S. Luxembourg: B268440

(the “Company”)

 

 

 

NOTICE OF AN EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS

 

 

 

1 Notice

 

An extraordinary general meeting of the shareholders of the Company (the “EGM”), will be held on 22 April 2025, at 1:00 p.m. (Central European Standard Time) at 35, avenue J. F. Kennedy, L-1855 Luxembourg, Grand Duchy of Luxembourg. The EGM will be held in front of a Luxembourg notary.

 

A shareholder who is entitled to attend and vote at the EGM is entitled to appoint one or more proxies to attend and vote instead of that shareholder in accordance with Section 4.2 of this notice, and such proxyholder need not be a shareholder of the Company.

 

2 Agenda of the EGM

 

The EGM will be held for the purpose of considering and voting on the following agenda points:

 

1 After acknowledging that (x) the transfer of the central administration (administration centrale) and registered office (siège social) of the Company from the Grand Duchy of Luxembourg to the Cayman Islands, and the setting of the registered office at c/o Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman KY1-9009, Cayman Islands and the change of nationality of the Company, as approved by the shareholders of the Company during an extraordinary general meeting of the shareholders held in front of a Luxembourg notary on 27 December 2024 are not yet effective since the condition to which the effectiveness of such resolution was subject has not been fulfilled and (y) that as a consequence, the laws applicable to the Company are still the laws of the Grand Duchy of Luxembourg, to approve as a special resolution the amendment and restatement of the Company’s existing amended and restated memorandum and articles (“A&R M&A”) and the adoption of a new set of articles of association in accordance with Luxembourg company laws (the “Articles”), in substitution for and to the entire exclusion of the Company’s A&R M&A, and, as part of such amendment and restatement:

 

(i) to restate its corporate object, so that the corporate object of the Company will read as follows:

 

“The object of the Company is the acquisition, holding and disposal of interests in Luxembourg and/or in foreign companies and undertakings, as well as the administration, development and management of such interests.

 

The Company may provide loans and financing in any other kind or form or grant guarantees or security in any other kind or form, for the benefit of the companies and undertakings forming part of the group of which the Company is a member.

 

 

Moolec Science SA EGM

1

 


 

 

The Company may also invest in real estate, in intellectual property rights or any other movable or immovable assets in any kind or form.

 

The Company may borrow in any kind or form and issue bonds, notes or any other debt instruments as well as warrants or other share subscription rights.

 

In a general fashion, the Company may carry out any commercial, industrial or financial operation, which it may deem useful in the accomplishment and development of its object.”

 

(ii) to acknowledge the report of the board of directors of the Company drawn up in accordance with article 420-26 paragraph (5) sub-paragraph 3 of the Luxembourg law of 10 August 1915 on commercial companies, as amended; and

 

(iii) to approve the creation of an authorised capital in an amount of five billion United States dollars (USD 5,000,000,000.-) divided into five hundred billion (500,000,000,000) shares with a nominal value of one cent (USD 0.01) each, and to give to the board of directors of the Company the authorization to realise increases of the issued share capital of the Company within the limits of the authorised capital of the Company so created and, in particular for that purpose, to determine the time, date, conditions and price of any share issue and to remove or limit the preferential subscription right of the existing shareholders of the Company to any such share issue for a period ending five (5) years after the date of the extraordinary general meeting of shareholders creating an authorised capital.

 

The full text of the special resolution to be voted upon at the EGM excluding the text of the Articles, which is set forth in Schedule 1 hereto and published on the Company website https://ir.moolecscience.com/ is as follows:

 

The general meeting of the shareholders of the Company resolved, as a special resolution to:

 

(i) acknowledge that the transfer of the central administration (administration centrale) and registered office (siège social) of the Company from the Grand Duchy of Luxembourg to the Cayman Islands, and the setting of the registered office at c/o Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman KY1-9009, Cayman Islands and the change of nationality of the Company, as approved by the shareholders of the Company during an extraordinary general meeting of the shareholders held in front of a Luxembourg notary on 27 December 2024 are not yet effective since the condition to which the effectiveness of such resolution was subject has not been fulfilled; that as a consequence, the laws applicable to the Company are still the laws of the Grand Duchy of Luxembourg;

 

(ii) acknowledge the report of the board of directors of the Company drawn up in accordance with article 420-26 paragraph (5) sub-paragraph 3 of the Luxembourg law of 10 August 1915 on commercial companies, as amended;

 

(iii) create an authorised capital in an amount of five billion United States dollars (USD 5,000,000,000.-) divided into five hundred billion (500,000,000,000) shares with a nominal value of one cent (USD 0.01) each, and to give to the board of directors of the Company the authorization to realise increases of the issued share capital of the Company within the limits of the authorised capital of the Company so created and, in particular for that purpose, to determine the time, date, conditions and price of any share issue and to remove or limit the preferential subscription right of the existing shareholders of the Company to any such share issue for a period ending five (5) years after the date of the extraordinary general meeting of shareholders creating an authorised capital; and

 

 

Moolec Science SA EGM

2

 


 

 

(iv) fully amend and restate the A&R M&A in substitution for and to the entire exclusion of the Company’s A&R M&A, including its corporate object with immediate effect and to adopt the Articles set forth in Schedule 1 hereto and, accordingly, the said Articles shall now read as set out in Schedule 1 hereto and as published on the Company website https://ir.moolecscience.com/

 

2 Subject to the adoption of the resolution corresponding to the previous agenda items, to abolish the nominal value of the shares, so that the value of each share will forthwith be its accounting par value as it results from the issued share capital.

 

3 Subject to adoption of the resolutions corresponding to the previous agenda items, to approve the further amendment of the first paragraph of article 5 and the first paragraph of article 6 of the Articles of the Company, in order to reflect the resolution to be adopted under agenda item 2.

 

4 To acknowledge current report on Form 6-K (File No. 001-41586) furnished to the United Stated Securities and Exchange Commission on March 14, 2025, relating to the Nasdaq Staff Determination Letter received by the Company, and to approve, subject to the adoption of the resolutions corresponding to the previous agenda items, a share consolidation of all the shares of the Company, having an accounting par value (the “Existing Shares”), by means of a reverse stock split at a consolidation ratio to be set between 2:1 and 10:1 (the “Consolidation Ratio”) by the board of directors of the Company, and to be implemented by the board of directors of the Company on a date which shall be no later than 6 September 2025 (the “RSS Effective Date”), further subject to approval of the resolutions to be taken on the basis of the below agenda items and to approve the round-up treatment of Existing Shares that cannot be consolidated into a whole number of consolidated shares (the “Share Consolidation”).

 

5 Subject to adoption of the resolutions corresponding to the previous agenda items, to approve the amendment of the first paragraph of article 5 and the first paragraph of article 6 of the Articles of the Company, in order to reflect the consolidation of the Existing Shares pursuant to the Consolidation Ratio.

 

6 Subject to adoption of the resolutions corresponding to the previous agenda items, to delegate all powers to the board of directors of the Company to take all steps required to implement the foregoing resolutions of the shareholders, including to set the Consolidation Ratio, to set the RSS Effective Date, to issue shares under the authorised capital of the Company or to allocate shares held in treasury by the Company, to confirm the amendment of the first paragraph of article 5 and the first paragraph of article 6 of the Articles of the Company, to update the share register of the Company and to do any and all formalities in connection therewith.

 

 

Moolec Science SA EGM

3

 


 

 

7 Subject to adoption of the resolutions corresponding to the previous agenda items, to approve, as described in the prospectus contained in a registration statement (File No. 333-284744) filed with the United States Securities and Exchange Commission, (i) the transfer of the central administration (administration centrale), and registered office (siège social) of the Company by way of continuation from the Grand Duchy of Luxembourg to the Cayman Islands, with continuation of legal personality without interruption or suspension and to designate the registered office at c/o Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman KY1-9009, Cayman Islands (the “Migration”), with effect from the date of issue of a certificate of registration by way of continuation to the Cayman Islands as an exempted company by the Registrar of Companies in the Cayman Islands (the “Effective Date”) and (ii) the continuation of the Company as an exempted company limited by shares in the Cayman Islands, the submission of the Company to the laws of the Cayman Islands and the adoption of the legal form of a Cayman Islands exempted company limited by shares under the laws of the Cayman Islands, each as from the Effective Date.

 

8 Subject to adoption of the resolutions corresponding to the previous agenda items, to approve that the name of the Company shall remain “Moolec Science SA” as from the Effective Date.

 

9 Subject to approval of the Migration, to fully restate the Articles and adopt new memorandum and articles of association (with such variations as required to reflect the Share Consolidation) in substitution for and to the exclusion of, the Company’s existing Articles in order to comply with the laws of the Cayman Islands, as a consequence of the Company becoming a Cayman Islands exempted company limited by shares, as from the Effective Date.

 

The Company’s object shall be changed to “The Company’s objects are unrestricted. As provided by section 7(4) of the Companies Act (Revised), the Company has full power and authority to carry out any object not prohibited by any law of the Cayman Islands”.

 

10 Subject to adoption of the resolutions corresponding to the previous agenda items, to acknowledge the composition of the board of directors of the Company as from the Effective Date will remain as per the composition of the board of directors of the Company as at the date hereof.

 

11 Subject to adoption of the resolutions corresponding to the previous agenda items, to approve that the place where the existing books and records of the Company shall be kept as from the Effective Date shall be c/o Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman KY1-9009, Cayman Islands.

 

12 Subject to adoption of the resolutions corresponding to the previous agenda items, to authorise the board of directors of the Company and each of Linklaters LLP, Ogier (Cayman) LLP and Ogier Global (Cayman) Limited to take all actions required in connection with the Migration, the deregistration of the Company in the Grand Duchy of Luxembourg and the filing of all necessary documents related to the foregoing with the Registrar of Companies in the Cayman Islands.

 

 

Moolec Science SA EGM

4

 


 

 

3 Key dates

 

7 April 2025, at 11:59 p.m. (Eastern Daylight Time) Record Date
18 April 2025, at 11:59 p.m. (Eastern Daylight Time) Deadline to submit proxies
22 April 2025, at 1:00 p.m. (Central European Standard Time) EGM

 

4 Right to participate at the EGM, and voting procedures

 

4.1 Shareholders

 

The holders of shares in the Company who comply with the procedures below, and who hold shares on the record on 7 April 2025, at 11:59 p.m. (Eastern Daylight Time) (the “Record Date”) are eligible to attend and vote at the EGM

 

Article 11.12 of the A&R M&A states that “a resolution put to a vote at the meeting shall be decided on a show of hands unless before, or on, the declaration of the result of the show of hands, a poll is duly demanded.”

 

4.2 Voting procedure

 

The Company urges each shareholder to cast its vote at the EGM by completing, signing, dating and returning the form of proxy made available by the Company for use at the EGM in accordance with the instructions below (the “Proxy”).

 

Each Proxy must be submitted in accordance with the information contained therein such that it is received no later than on 18 April 2025, at 11:59 p.m. (Eastern Daylight Time) (the “Voting Deadline”).

 

The Company has sent by post to each shareholder as of the Record Date, the notice and a form of Proxy, together with a control number.

 

Shareholders may also vote in person at the EGM. All shareholders must present valid government issued photo identification documentation to attend the EGM, as well as a proof of ownership of shares of the Company as at the Record Date. Admittance of shareholders to the EGM and acceptance of Proxies will be governed by Luxembourg law and the A&R M&A.

 

A holder of shares held through the operator of a securities settlement system of with a depositary wishing to attend the EGM must provide the Company with a certificate issued by such operator or depositary certifying the number of shares recorded in the relevant account on the Record Date. Such certificate must be provided to the Company no later than three (3) business days prior to the date of the EGM. If you plan to attend the EGM, you are kindly requested to notify the Company thereof in writing and provide your name, address and telephone number and any other necessary materials before 18 April 2025, at 11:59 p.m. (Eastern Daylight Time) to the Company at 17, boulevard F.W. Raiffeisen, L-2411 Luxembourg, Grand Duchy of Luxembourg or by email to florencia@moolecscience.com.

 

4.3 Supporting documents and information

 

Information concerning the matters to be considered and voted upon at the EGM, together with the relevant supporting documentation, including the articles of association of the Company, governed by Luxembourg laws, to be adopted in order to resolve on the Share Consolidation and the Migration in front of the Luxembourg notary and the new memorandum and articles of the Company, governed by Cayman Islands laws, to be adopted in the context of the Migration in order to comply with the laws of the Cayman Islands, are available to the shareholders for physical inspection during business hours at 17, boulevard F.W. Raiffeisen, L-2411 Luxembourg, Grand Duchy of Luxembourg and electronically on the Company’s website https://ir.moolecscience.com/.

 

Shareholders have the right to ask questions about items on the agenda of the EGM during the EGM. The Company will on a best efforts basis provide responses to the questions at the EGM.

 

 

Moolec Science SA EGM

5

 


 

 

 

4.4 Personal Data

 

In connection with the EGM, the Company is required to collect certain data including personal data in order to confirm the identity of individual shareholders or shareholder representatives for the purpose of carrying out the EGM and to comply with applicable laws and regulations. Such personal data may include the contact details and identification details of shareholders (name, address, date of birth, ID number, etc.). By submitting a Proxy, you confirm that you understand the fact that the personal data will be collected, processed and used in connection with the EGM including for the purpose of the organization of the EGM and the voting on the resolutions in accordance with the Company’s articles of association and applicable laws.

 

If you choose not to share personal data with us, you will not be able to participate and vote in the EGM.

 

The Company is the data controller for any personal data that is collected in connection with the EGM. A controller is the entity that decides why and how your information is processed.

 

We may disclose your personal data to certain entities to the extent required to perform the various activities related to the EGM. In particular, your personal data may be disclosed to Linklaters LLP, Ogier (Cayman) LLP and Continental Stock Transfer & Trust Company. If we do this, we will require such third parties to protect the confidentiality and privacy of the personal data and to use such information solely for the purposes for which such information is shared. The Company will ensure that transfers of personal data to such third parties will be carried out in compliance with applicable data protection laws and regulations and in particular, will establish suitable safeguards to ensure that such transfers are carried out in compliance with applicable data protection laws and regulations.

 

Personal data will be retained no longer than necessary for the purposes indicated hereinabove, unless otherwise required by applicable laws or regulations.

 

Under certain circumstances, you have rights under data protection laws in relation to your personal data. In particular, you have a right to (i) access your personal data, (ii) be informed about how personal data is used, (iii) have inaccurate personal data rectified, (iv) data portability, and, in certain circumstances, have the right to have your personal data erased, restrict processing of your personal data and object to the processing thereof. To exercise these rights or if you have any other data protection queries, please contact us by email at florencia@moolecscience.com.

 

More information on how we process your data and your rights with respect thereto can be found in our privacy policy, available on our website https://ir.moolecscience.com/.

 

Luxembourg, 5 April 2025

 

The Board of Directors of Moolec Science SA

 

 

Moolec Science SA EGM

6

 


 

Schedule 1

 

CHAPTER I. FORM, NAME, REGISTERED OFFICE, OBJECT, DURATION

 

Article 1. Form, Name

 

A société anonyme (the “Company”) is governed by the laws of the Grand Duchy of Luxembourg, in particular the law of 10 August 1915 on commercial companies, as amended (the “Laws”) and by these articles of association (the “Articles of Association”).

 

The Company exists under the name of “Moolec Science SA”.

 

Article 2. Registered Office

 

The Company will have its registered office in the City of Luxembourg.

 

The registered office may be transferred to any other place within the Grand Duchy of Luxembourg by a resolution of the Board of Directors (as defined below). The Board of Directors shall arrange that the Articles of Association are amended to reflect such transfer.

 

Branches or other offices may be established either in the Grand Duchy of Luxembourg or abroad by a resolution of the Board of Directors.

 

In the event that, in the view of the Board of Directors, extraordinary political, economic or social developments occur or are imminent that would interfere with the normal activities of the Company at its registered office or with the ease of communications with this office or between this office and persons abroad, the Company may temporarily transfer the registered office abroad, until the complete cessation of these abnormal circumstances. These temporary measures will have no effect on the nationality of the Company, which, notwithstanding the temporary transfer of the registered office, will remain a company governed by the Laws. These temporary measures will be taken and notified to any interested parties by the Board of Directors.

 

In accordance with the provisions of the Laws, the Company may be converted into a foreign law company without being dissolved or liquidated or put into liquidation and, if applicable, without interruption of its legal personality, provided that the law of the destination country does not oppose such conversion. 

 

Article 3. Object

 

The object of the Company is the acquisition, holding and disposal of interests in Luxembourg and/or in foreign companies and undertakings, as well as the administration, development and management of such interests.

 

The Company may provide loans and financing in any other kind or form or grant guarantees or security in any other kind or form, for the benefit of the companies and undertakings forming part of the group of which the Company is a member.

 

The Company may also invest in real estate, in intellectual property rights or any other movable or immovable assets in any kind or form.

 

The Company may borrow in any kind or form and issue bonds, notes or any other debt instruments as well as warrants or other share subscription rights.

 

In a general fashion, the Company may carry out any commercial, industrial or financial operation, which it may deem useful in the accomplishment and development of its object.

 

 

Moolec Science SA EGM

Sch 1-1

 


 

Article 4. Duration

 

The Company is formed for an unlimited duration.

 

CHAPTER II. CAPITAL, SHARES

 

Article 5. Share Capital

 

The Company’s share capital is set at four hundred one thousand two hundred sixty-eight United States dollars and forty cents (USD 401,268.40), represented by forty million one hundred twenty-six thousand eight hundred forty (40,126,840) shares with a nominal value of one cent (USD 0.01) each (the “Shares”).

 

In addition to the share capital, a premium account may be established to record any premium paid on any Share in addition to its nominal value. The premium account shall constitute a distributable reserve and may notably be used for the payment of the price for any Shares which the Company may repurchase from its shareholder(s), to offset any net realised losses, to make distributions to the shareholder(s) or to allocate funds to the legal reserve.

 

Distributable reserve accounts may be established to record contributions to the Company made by existing shareholders without issuance of Shares. Any such reserve shall constitute a distributable reserve and may notably be used to provide for the payment of the price of any Shares which the Company may repurchase from its shareholder(s), to offset any net realised losses, to make distributions to the shareholder(s) or to allocate funds to the legal reserve.

 

Article 6. Authorised Capital – Free Shares

 

The authorised capital of the Company (excluding the issued share capital) is set at five billion United States dollars (USD 5,000,000,000.-) divided into five hundred billion (500,000,000,000) Shares with a nominal value of one cent (USD 0.01) each.

 

The Board of Directors is authorised, up to the maximum amount of the authorised capital, to (i) increase the issued share capital in one or several tranches with or without share premium, against payment in cash or in kind, by conversion of claims on the Company or in any other manner; (ii) issue subscription and/or conversion rights in relation to new shares or instruments within the limits of the authorised capital under the terms and conditions of warrants (which may be separate or linked to Shares, bonds, notes or similar instruments issued by the Company), convertible bonds, notes or similar instruments; (iii) determine the place and date of the issue or successive issues, the issue price, the terms and conditions of the subscription of and paying up on the new shares and instruments and (iv) remove or limit the statutory preferential subscription right of the shareholders.

 

The Board of Directors may authorise any person to accept on behalf of the Company subscriptions and receive payment for Shares or instruments issued under the authorised capital.

 

The Board of Directors is further authorised to make an allotment of existing or newly issued shares without consideration to the following persons:

 

(a) employees of the Company or certain categories amongst those;

 

(b) employees of companies or economic interest grouping in which the Company holds directly or indirectly at least fifty per cent (50%) of the share capital or voting rights;

 

(c) employees of companies or economic interest grouping in which at least fifty per cent (50%) of the share capital or voting rights is held directly or indirectly by a company which holds directly or indirectly at least fifty per cent (50%) of the share capital of the Company;

 

 

Moolec Science SA EGM

Sch 1-2

 


 

(d) members of the corporate bodies of the Company or of the companies or economic interest grouping listed in point (b) to (c) above or certain categories amongst those.

 

The above authorisations are valid for a period ending five (5) years after the latest of (i) the date of the deed of incorporation of the Company or (ii) the date of the deed enacting the renewal of such authorisations. The above authorisations may be renewed, increased or reduced by a resolution of the General Meeting voting with the quorum and majority rules set for the amendment of the Articles of Association. The shares to be issued upon exercise or conversion of any warrants (which may be separate or linked to Shares, bonds, notes or similar instruments issued by the Company), convertible bonds, notes or similar instruments may be issued beyond the initial authorised capital period of five (5) years as long as such instruments were issued within the relevant initial authorized capital period of five (5) years.

 

Following each increase of the issued share capital in accordance with this Article 6, Article 5 will be amended so as to reflect the capital increase. Any such amendment will be recorded in a notarial deed upon the instructions of the Board of Directors or of any person duly authorised by the Board of Directors for this purpose.

 

Article 7. Increase and Reduction of Capital – Acquisition of own Shares

 

The share capital and/or authorised capital of the Company may be increased or reduced by a resolution of the General Meeting adopted in compliance with the quorum and majority rules set for the amendment of the Articles of Association.

 

The new shares to be subscribed for by contribution in cash will be offered by preference to the existing shareholders in proportion to the part of the capital which those shareholders are holding. The Board of Directors shall determine the period within which the statutory preferential subscription rights (“PSRs”) shall be exercised (the “Subscription Period”) and the PSRs shall be freely negotiable during the Subscription Period. If, at the end of the Subscription Period, not all PSRs have been exercised, the PSRs shall immediately lapse and the Board of Directors may decide that any person (including third parties) may participate in the capital increase by subscribing to the shares which have not been subscribed through the exercise of PSRs during the Subscription Period.

 

Notwithstanding the above, the Board of Directors, within the limit of the authorisation under Article 6 or, the General Meeting, voting in compliance with the quorum and majority rules set for any amendment of the Articles of Association may limit or withdraw the PSRs.

 

The Company may acquire or repurchase Shares.

 

Article 8. Shares

 

8.1 Each Share entitles to one (1) vote.

 

8.2 A shareholder may individually undertake not to exercise, permanently or temporarily, all or part of its voting rights. Such a waiver binds the relevant shareholder and the Company as from its notification to the Company.

 

8.3 The rights and obligations attached to all Shares shall be identical except to the extent otherwise provided by the Articles of Association or by the Laws.

 

8.4 The co-owners of Shares must be represented towards the Company by one (1) joint representative, whether appointed amongst them or not.

 

8.5 The Shares will be in the form of registered shares only.

 

8.6 A register of shares shall be kept by the Company at its registered office, where it shall be available for inspection by any shareholder. This register shall contain the precise designation of each shareholder and the indication of the number of Shares held, the indication of the payments made on the Shares as well as the transfers of Shares and the dates thereof. Ownership of shares will be established by inscription in the said register or in the event separate registrars have been appointed pursuant to Article 8.8, in such separate register(s).

 

 

Moolec Science SA EGM

Sch 1-3

 


 

8.7 The Company may appoint registrars in different jurisdictions who may each maintain a separate register for the Shares entered therein. Shareholders may elect to be entered into one of these registers and to transfer their Shares to another register so maintained. The Board of Directors may however impose transfer restrictions for Shares in compliance with the requirements of the jurisdiction applicable to the Shares at that time. A transfer to the register kept at the Company’s registered office may always be requested.

 

8.8 Subject to the provisions of Articles 8.10 and 8.11, the Company may consider the person in whose name the Shares are registered in the register of shareholders as the full owner of such Shares. In the event that a holder of Shares does not provide an address in writing to which all notices or announcements from the Company may be sent, the Company may permit a notice to this effect to be entered into the register of shareholders and such holder’s address will be deemed to be at the registered office of the Company or such other address as may be so entered by the Company from time to time, until a different address shall be provided to the Company by such holder in writing. The holder may, at any time, change his address as entered in the register of shareholders by means of written notification to the Company.

 

8.9 The Shares may be held by a holder through a securities settlement system or a Depositary (as this term is defined below). The holder of Shares held in such fungible securities accounts has the same rights and obligations as if such holder held the Shares directly. The Shares held through a securities settlement system or a Depositary shall be recorded in an account opened in the name of the holder and may be transferred from one account to another in accordance with customary procedures for the transfer of securities in book-entry form. However, the Company will make dividend payments, if any, and any other payments in cash, shares or other securities, if any, only to the securities settlement system or Depositary recorded in the register of shareholders or in accordance with the instructions of such securities settlement system or Depositary. Such payment will grant full discharge of the Company’s obligations in this respect.

 

8.10 All communications and notices to be given to a registered shareholder shall be deemed validly made if made to the latest address communicated by the shareholder to the Company in accordance with Article 8.8 or, if no address has been communicated by the shareholder, the registered office of the Company or such other address as may be so entered by the Company in the register from time to time according to Article 8.8.

 

8.11 Where Shares are recorded in the register of shareholders in the name of or on behalf of a securities settlement system or the operator of such system and recorded as book-entry interests in the accounts of a professional depositary or any sub-depositary (any depositary and any sub-depositary being referred to as a “Depositary”), the Company – subject to having received from the Depositary a certificate (or such other document as accepted by the Company) in proper form – will permit the Depositary of such book-entry interests to exercise the rights attaching to the Shares corresponding to the book-entry interests of the relevant holder, including receiving notices of general meetings, admission to and voting at general meetings, and shall consider the Depositary to be the holder of the Shares corresponding to the book-entry interests for purposes of this Article 8 of the present Articles of Association. The Board of Directors may determine the formal requirements with which such certificates (or such other document as accepted by the Company) must comply and the exercise of the rights in respect of such Shares may in addition be subject to the internal rules and procedures of the securities settlement system.

 

 

Moolec Science SA EGM

Sch 1-4

 


 

8.12 Any person who is required to report ownership of Shares on Schedule 13D or 13G pursuant to Rule 13d-1 or changes in such ownership pursuant to Rule 13d-2, each as promulgated by the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, must notify the Company’s Board of Directors promptly following any reportable acquisition or disposition, and in no event later than the filing date of such Schedule 13D or 13G, of the proportion of Shares held by the relevant person as a result of the acquisition or disposal.

 

Article 9. Transfer of Shares

 

The Shares are freely transferable in accordance with the provisions of the Law, subject to any contractual restrictions or restrictions on transfer under applicable securities laws of any jurisdiction to which the Shares are subject.

 

Without prejudice to the conditions for transfer by book entries provided for in Article 8.10 of these Articles of Association, any transfer of Shares will be registered in the register of shares by a declaration of transfer entered into the register of shares, dated and signed by the transferor and the transferee or by their representative(s) as well as in accordance with the rules on the transfer of claims laid down in article 1690 of the Luxembourg Civil Code. Furthermore, the Company may accept and enter into the register of shares any transfer referred to in any correspondence or other document recording the consent of the transferor and the transferee.

 

Ownership of a Share carries implicit acceptance of the Articles of Association and of the resolutions validly adopted by the General Meeting.

 

A transfer of Shares in breach of provisions of the Articles of Association shall be null and void.

 

Article 10. Incapacity, Death, Suspension of Civil Rights, Bankruptcy or Insolvency of a shareholder

 

The incapacity, death, suspension of civil rights, bankruptcy, insolvency, liquidation, or any other similar event affecting one or more shareholder(s) does not put the Company into liquidation.

 

CHAPTER III. BOARD OF DIRECTORS, AUDITORS

 

Article 11. Board of Directors

 

The Company shall be managed by a board of directors (the “Board of Directors”).

 

The Board of Directors shall be composed of not less than five (5) members (the “Directors”), who may but do not need to be shareholders of the Company themselves.

 

If and as long as the Company has only one (1) shareholder, the Board of Directors may comprise one (1) Director only.

 

Each Director will be appointed by the General Meeting by a simple majority of votes cast. The General Meeting shall determine the number of Directors and the duration of their mandate. The resolutions of the General Meeting approving the appointment of a Director shall require a separate vote for each individual candidate Director.

 

 

Moolec Science SA EGM

Sch 1-5

 


 

The duration of the mandate of any Directors appointed shall be determined so as not to exceed the date of the annual general meeting of shareholders of the Company approving the annual accounts of the next financial year following their appointment.

 

Each Director is eligible for re-appointment for successive terms and may be removed at any time, with or without cause by a resolution of the General Meeting.

 

In the event of a vacancy on the Board of Directors, the remaining Directors may elect by co-optation a new Director to fill such vacancy until the next General Meeting, which shall ratify such co-optation or elect a new Director instead.

 

Article 12. Powers of the Board of Directors

 

The Board of Directors is vested with the broadest powers to perform all acts necessary or useful to accomplish the Company’s object.

 

All powers not expressly reserved by the Articles of Association or by the Laws to the General Meeting or to the Auditor(s) (as defined below) shall be within the competence of the Board of Directors.

 

Article 13. Delegation of Powers - Representation of the Company

 

The Board of Directors may delegate the daily management of the Company and the representation of the Company for that daily management to one or more persons or committees of its choice.

 

The Board of Directors may create one or several committees. The composition and the powers of such committee(s), the terms of the appointment, removal, remuneration and duration of the mandate of its/their members, as well as its/their rules of procedure are determined by the Board of Directors. The Board of Directors shall be in charge of the supervision of the activities of the committee(s).

 

The Board of Directors may also grant other special powers of attorney or entrust permanent or temporary tasks to one or more persons of its choice. Such persons shall exercise the tasks entrusted to them under the supervision of the Board of Directors.

 

The remuneration and other benefits granted to the person(s) to whom the daily management has been delegated must be reported annually by the Board of Directors to the General Meeting.

 

The Company will be bound towards third parties by the individual signature of the sole Director or by the joint signatures of any three (3) Directors.

 

The Company will further be bound towards third parties by the joint signatures or single signature of any person(s) to whom the daily management of the Company has been delegated, for that daily management, or by the joint signatures or sole signature of any person(s) to whom any special power of attorney has been granted, but only within the limits of that special power of attorney.

 

Article 14. Meetings of the Board of Directors

 

The Board of Directors may appoint from among its members a chairperson (the “Chairperson”).

 

The Board of Directors will meet upon call by the Chairperson or by any Director in accordance with the provisions of this Article 14.

 

The Chairperson will preside over all meetings of the Board of Directors, except that in the absence of the Chairperson, the Board of Directors may appoint another Director as chairperson for the relevant meeting by a majority of the votes of the Directors present or represented at such meeting.

 

 

Moolec Science SA EGM

Sch 1-6

 


 

Except in case of urgency or with the prior consent of all those entitled to attend, which consent shall be recorded in the minutes of the meeting at least forty-eight (48) hours’ written notice of meetings of the Board of Directors shall be given in writing and transmitted by any means of communication allowing for the transmission of a written text. Any such notice shall specify the time and the place of the meeting, as well as the agenda and the nature of the business to be resolved upon. The notice may be waived by properly documented consent of each Director which consent shall be recorded in the minutes of the meeting. No separate notice is required for meetings held at times and places specified in a time schedule previously adopted by resolution of the Board of Directors.

 

The meetings of the Board of Directors shall be held in the Grand Duchy of Luxembourg or at such other place as the Board of Directors may from time to time determine.

 

Any Director may be represented at any meeting of the Board of Directors by appointing in writing, transmitted by any means of communication allowing for the transmission of a written text, another Director as his proxy. Any Director may represent one or more Directors.

 

The quorum for a valid meeting of the Board of Directors shall be the presence or the representation of at least half (1/2) of the Directors.

 

When the rules of a foreign stock exchange require that, at least once a year, only independent directors of the Company may hold a meeting of the Board of Directors, the quorum required for a meeting of the Board of Directors can be disregarded and the independent directors must all be present or represented at such meeting. The independent directors may appoint a chairman pro tempore at such meetings.

 

Resolutions of the Board of Directors in a meeting will be taken by a majority of the votes of the Directors present or represented at such meeting. The Chairperson shall have no casting vote in case of a tie.

 

Directors may participate in a meeting by conference call, videoconference or any other similar means of communication enabling thus several persons participating therein to simultaneously communicate with each other on a continuous basis. A meeting held using such means of communication is deemed to have taken place at the Company’s registered office.

 

A written resolution, signed by all the Directors and transmitted by any means of communication allowing for the transmission of a written text, is proper and valid as though it had been adopted at a meeting of the Board of Directors which was duly convened and held. Such a resolution may be documented in a single document or in several separate documents having the same content and each of them signed by one or several Directors. A written resolution passed in this way is deemed to have been taken at the Company’s registered office.

 

Article 15. Resolutions of the Board of Directors

 

The resolutions of the Board of Directors shall be recorded in writing.

 

The minutes of any meeting of the Board of Directors will be signed by the Chairperson or the chairperson of the meeting or by any three (3) Directors.

 

Copies or extracts of written resolutions or minutes, to be produced in judicial proceedings or otherwise, may be signed by the sole Director or by any three (3) Directors acting jointly.

 

In case of a sole Director, resolutions shall be documented in writing and signed by the sole Director.

 

 

Moolec Science SA EGM

Sch 1-7

 


  

Article 16. Management Fees and Expenses

 

Subject to approval by the General Meeting, Directors may receive a management fee for their management of the Company and may, in addition, be reimbursed for all other expenses whatsoever incurred by the relevant Director in relation to the management of the Company.

 

Article 17. Conflicts of Interest

 

If any Director has or may have a direct or indirect financial interest in any transaction which requires the approval of the Board of Director(s), that Director shall disclose that interest to the Board of Directors and shall not take part of any deliberation or vote on any such transaction.

 

Such transaction and such Director’s interest shall be disclosed in a special report to the next General Meeting before any resolution is passed.

 

In case of a sole Director, record is kept in writing of the transactions where the sole Director has such direct or indirect financial interest.

 

Where, due to a conflict of interests, the number of Directors required to be present or represented for a valid quorum is not reached, the Board of Directors may defer the decision to the General Meeting.

 

The foregoing paragraphs do not apply if the relevant transaction falls within the ordinary course of business of the Company and is entered into at arm’s length under market conditions.

 

No transaction between the Company and any other party shall be affected or invalidated by the mere fact that a Director (or any one of its directors, managers, officers or employees) is a director, manager, associate, member, shareholder, officer or employee of that other party. Any person related as described above to any company or firm with which the Company shall contract or otherwise engage in business shall not, by reason of such affiliation, be automatically prevented from considering, voting or acting upon any matters with respect to such contract or other business.

 

The provisions of this article apply mutatis mutandis to the persons to whom the Board of Directors has delegated the daily management of the Company, except that in case the Board of Directors has delegated the daily management of the Company to a single person, the decision shall be deferred to the Board of Directors.

 

Article 18. Directors’ Liability; Indemnification

 

Directors are not held personally liable for the indebtedness or other obligations of the Company. As agents of the Company, they are responsible for the performance of their duties. Subject to the exceptions and limitations listed in below and mandatory provisions of law, every person who is, or has been, a Director or officer of the Company (and his or her heirs, executors and administrators) shall be indemnified by the Company to the fullest extent permitted by law against liability and against all expenses reasonably incurred or paid by such person in connection with any claim, action, suit or proceeding which he becomes involved as a party or otherwise by virtue of his or her being or having been a director or officer of the Company, or, at the request of the Company, of any other company of which the Company is a shareholder or creditor and by which he is not entitled to be indemnified, and against amounts paid or incurred by him or her in the settlement thereof. The words “claim”, “action”, “suit” or “proceeding” shall apply to all claims, actions, suits or proceedings (civil, criminal or otherwise including appeals) actual or threatened and the words “liability” and “expenses” shall include without limitation attorneys’ fees, costs, judgments, amounts paid in settlement and other liabilities.

 

 

Moolec Science SA EGM

Sch 1-8

 


  

No indemnification shall be provided to any Director, officer or shareholder (i) against any liability by reason of willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of his or her office, (ii) with respect to any matter as to which he or she shall have been finally adjudicated to have acted in bad faith and not in the interest of the Company or (iii) in the event of a settlement, unless the settlement has been approved by a court of competent jurisdiction or by the Board of Directors.

 

The right of indemnification herein provided shall be severable, shall not affect any other rights to which any director or officer may now or hereafter be entitled, shall continue as to a person who has ceased to be such director or officer and shall inure to the benefit of the heirs, executors and administrators of such a person. Nothing contained herein shall affect or limit any rights to indemnification to which corporate personnel, including directors and officers, may be entitled by contract or otherwise under law. The Company shall specifically be entitled to provide contractual indemnification to and may purchase and maintain insurance for any corporate personnel, including directors and officers of the Company, as the Company may decide upon from time to time.

 

Article 19. Confidentiality

 

Even after cessation of their mandate or function, any Director, as well as any person who is invited to attend a meeting of the Board of Directors, shall not disclose information on the Company, the disclosure of which may have adverse consequences for the Company, unless such divulgation is required (i) by a legal or regulatory provision applicable to sociétés anonymes or (ii) for the public benefit.

 

Article 20. Auditors

 

The auditing of the Company may be entrusted to one or several auditors (commissaires) (the “Auditors”).

 

When so required by the Laws, the auditing of the Company must be entrusted to one or several approved statutory auditors (réviseurs d’entreprises agréés) (“Réviseurs”). When a Réviseur is appointed, no Auditor needs to be appointed.

 

The Auditors or Réviseurs, if any, will be appointed by the General Meeting, which will determine the number of Auditors or Réviseurs and the duration of their mandate. Each of them is eligible for re-appointment. Unless otherwise provided by the Laws, they may be removed at any time, with or without cause, by a resolution of the General Meeting.

 

CHAPTER IV. GENERAL MEETING

 

Article 21. Powers of the General Meeting

 

The general meeting of shareholders (the “General Meeting”) shall have such powers as are vested in it pursuant to the Articles of Association and the Laws.

 

Article 22. Annual General Meeting

 

An annual General Meeting shall be held in the Grand Duchy of Luxembourg within six (6) months of the end of the preceding financial year, except for the first annual General Meeting which may be held within eighteen (18) months from incorporation.

 

Article 23. Other General Meetings

 

The Board of Directors or the Auditor(s) (if any) may convene General Meetings (in addition to the annual General Meeting). Such meetings must be convened if shareholders representing at least ten per cent (10%) of the Company’s share capital so require.

 

General Meetings, including the annual General Meeting, will be held at the registered office of the Company or at such other place in the Grand Duchy of Luxembourg, and may be held abroad if, in the judgement of the Board of Directors, circumstances of force majeure so require.

 

 

Moolec Science SA EGM

Sch 1-9

 


  

Article 24. Notice of General Meetings

 

The shareholders shall meet in a General Meeting upon issuance of a convening notice in accordance with the Laws which shall specify the time and the place of the General Meeting as well as the agenda and the nature of the business to be resolved upon at the relevant General Meeting. The agenda for a General Meeting shall also describe any proposed changes to the Articles of Association and, if applicable, set out the text of those changes affecting the object or form of the Company. If the Shares are listed on a foreign stock exchange, the requirements of such foreign stock exchange applicable to the Company shall additionally be complied with.

 

If the Shares are listed on a foreign stock exchange, all shareholders of the Company (for the avoidance of doubt, including any registered shareholder, any Depositary and, without prejudice to any requirements as set out in any other provision of these Articles of Association, any holder of Shares) are entitled to be admitted to any General Meeting, provided, however, that the Board of Directors may determine a date and time preceding the General Meeting as the record date for admission to such meeting, which may not be less than five (5) calendar days before the date of such meeting (the “Record Date”).

 

Shareholders holding individually or collectively at least ten (10) per cent of the issued share capital of the Company, may request the addition of one or several new items on the agenda of the General Meeting. This right shall be exercised upon request of the shareholders in writing submitted to the Company by registered letter at the address of the registered office of the Company. The requests shall include the details requested in the convening notice. The requests from the shareholders shall be received by the Company no later than five (5) calendar days before the General Meeting.

 

Article 25. Attendance - Representation

 

Each shareholder is entitled to attend and speak at any General Meeting.

 

A shareholder may be represented at any General Meeting by another person (who does not need to be a shareholder) appointed in writing (transmitted by any means of communication allowing for the transmission of a written text) as a proxyholder by the shareholder. A proxyholder may represent more than one (1) shareholder.

 

Shareholders taking part in a meeting by conference call, through video conference or by any other means of communication allowing for their identification, allowing all persons taking part in the meeting to hear one another on a continuous basis and allowing for an effective participation of all such persons in the meeting, are deemed to be present for the computation of the quorums and votes, subject to such means of communication being made available at the place of the meeting. A General Meeting held in this way is deemed to have taken place at the Company’s registered office.

 

Article 26. Proceedings

 

Any General Meeting shall be presided over by the Chairperson or, in the absence of the Chairperson, by a person designated by the Board of Directors or, in the absence of such designation, by a resolution of the General Meeting.

 

The chairperson of the General Meeting shall appoint a secretary.

 

By resolution of the General Meeting one (1) scrutineer shall be appointed from the persons attending the General Meeting.

 

The chairperson, the secretary and the scrutineer together form the board of the relevant General Meeting.

 

 

Moolec Science SA EGM

Sch 1-10

 


  

In connection with each General Meeting, the Board of Directors is authorised to provide such rules of deliberations and such conditions for allowing shareholders to take part in the meeting as the Board of Directors deems appropriate.

 

Except to the extent inconsistent with the rules and conditions as adopted by the Board of Directors, the person presiding over the General Meeting shall have the power and authority to prescribe such additional rules and conditions and to do all such acts as, in the judgment of such person, are appropriate for the proper conduct of the meeting. Such rules and conditions, whether adopted by the Board of Directors or prescribed by the person presiding over the meeting, may include, in each case to the extent permitted by applicable law:

 

(a) determining the order of business for the meeting;

 

(b) rules and procedures for maintaining order at the meeting and the safety of those present;

 

(c) limitations on attendance at or participation in the meeting to shareholders of record, their duly authorised and constituted attorneys or such other persons as the person presiding over the meeting shall determine;

 

(d) restrictions on entry to the meeting after the time fixed for the commencement thereof; and

 

(e) limitations on the time allotted to questions or comments by participants.

 

Article 27. Adjournment

 

Without limiting the generality of Article 26 and irrespective of the agenda, the Board of Directors may adjourn any General Meeting in accordance with the formalities and time limits stipulated for by the Law.

 

Such adjournment automatically cancels any resolution already adopted prior thereto.

 

The adjourned General Meeting has the same agenda as the first one. Shares and proxies regularly deposited in view of the first meeting remain validly deposited for the second one.

 

Article 28. Voting at General Meetings

 

An attendance list indicating the name of each shareholder and the number of Shares for which he votes is signed by or on behalf of each shareholder present or represented by proxy, prior to the start of the General Meeting.

 

The Board of Directors may in its sole discretion authorize each shareholder to vote at a General Meeting through a signed voting form sent by post, electronic mail, facsimile or any other means of communication to the Company’s registered office or to the address specified in the convening notice. Subject to such authorisation by the Board of Directors, the shareholders may only use voting forms provided by the Company which contain at least the date, place and time of the meeting, the agenda of the meeting and the text of the proposed resolutions. For each resolution, the form must contain three boxes allowing the shareholder to vote in favor thereof, against, or abstain from voting by ticking the appropriate box. For the avoidance of doubt, shareholders may not vote by voting forms where the Board of Directors has not authorised such voting method for a given General Meeting.

 

Voting forms which, for a proposed resolution, do not show (i) a vote in favor of the proposed resolution, (ii) a vote against the proposed resolution or (iii) an abstention from voting on the proposed resolution, are void with respect to such resolution. If a shareholder votes by means of a voting form, the voting form shall be deposited at the registered office of the Company or with an agent of the Company duly authorised to receive such voting forms. The Company shall only take into account voting forms received no later than three (3) business days prior to the date of the General Meeting to which they relate. The Board of Directors may set a shorter period for the submission of the voting forms.

 

 

Moolec Science SA EGM

Sch 1-11

 


  

If a shareholder votes by means of proxy, the proxy shall be deposited at the registered office of the Company or with an agent of the Company duly authorised to receive such proxies. The Company shall only take into account proxies received no later than three (3) business days prior to the date of the General Meeting to which they relate. The Board of Directors may set a shorter period for the submission of the proxies.

 

A holder of Shares held through the operator of a securities settlement system or with a Depositary wishing to attend a General Meeting must provide the Company with a certificate issued by such operator or Depositary certifying the number of Shares recorded in the relevant account on the Record Date. Such certificate must be provided to the Company no later than three (3) business days prior to the date of such general meeting. If such holder of shares votes by means of a proxy, Article 28 of these Articles of Association shall apply.

 

Resolutions the adoption of which is not subject to the quorum and the majority requirements for an amendment of the Articles of Association, shall be adopted, irrespective of the number of Shares represented, by a simple majority of votes cast.

 

For resolutions the adoption of which is subject to the quorum and majority requirements for an amendment of the Articles of Association, the quorum shall be at least one half (1/2) of all the Shares issued and outstanding and the resolutions shall be adopted by a two thirds (2/3rds) majority of the votes cast. If the said quorum is not reached at a first meeting, a second meeting may be convened and resolutions shall be adopted, irrespective of the number of Shares represented, by a two thirds (2/3rds) majority of the votes cast.

 

The resolutions of the General Meeting approving the appointment of a Director shall require a separate vote for each individual candidate Director.

 

Article 29. Minutes

 

The minutes of a General Meeting shall be signed by the members of the board of that General Meeting and may be signed by or on behalf of any shareholders, who so request.

 

CHAPTER V. FINANCIAL YEAR, FINANCIAL STATEMENTS, DISTRIBUTION OF PROFITS

 

Article 30. Financial Year

 

The Company’s financial year begins on the first day of July and ends on the last day of June of each calendar year.

 

Article 31. Adoption of Financial Statements

 

After the end of each financial year, the Board of Directors draws up the annual financial statements of the Company in accordance with the Laws.

 

The annual statutory and/or consolidated financial statements are submitted to the General Meeting for approval.

 

Each shareholder or his representative may also peruse the financial statements of the Company at the registered office of the Company.

 

 

Moolec Science SA EGM

Sch 1-12

 


 

Article 32. Distribution of Profits

 

From the annual net profits of the Company, at least five per cent (5%) shall each year be allocated to the reserve required by Laws (the “Legal Reserve”). That allocation to the Legal Reserve will cease to be required as soon and as long as the Legal Reserve amounts to ten per cent (10%) of the amount of the share capital of the Company.

 

The General Meeting shall resolve how the remainder of the annual net profits, after allocation to the Legal Reserve in accordance with the previous paragraph, will be disposed of by allocating the whole or part of the remainder to a reserve or to a provision, by carrying it forward to the next following financial year or by distributing it, together with carried forward profits, distributable reserves or share premium to the shareholder(s), each Share entitling to the same proportion in such distributions.

 

Subject to the provisions of the Laws and in compliance with the provisions in the previous two paragraphs, the Board of Directors may resolve that the Company pays out an interim dividend to the shareholders. The Board of Directors shall set the amount and the date of payment of the interim dividend.

 

Any share premium, assimilated premium or other distributable reserve may be freely distributed to the shareholders subject to the provisions of the Law and the Articles of Association.

 

CHAPTER VI. DISSOLUTION, LIQUIDATION

 

Article 33. Dissolution, Liquidation

 

The Company may be dissolved by a resolution of the General Meeting adopted in compliance with the quorum and majority rules set for any amendment of the Articles of Association.

 

Should the Company be dissolved, the liquidation will be carried out by the Board of Directors or such other person(s) (who may be physical persons or legal entities) appointed by the General Meeting. The General Meeting shall also determine the powers and the compensation (if any) of such other person(s).

 

After settlement of all the debts and liabilities of the Company, including the expenses of liquidation, the net liquidation proceeds shall be distributed to the shareholder(s) in compliance with the same preference as set out for dividend distributions.

 

In case the Company has only one (1) shareholder, it may also be dissolved without liquidation in accordance with article 1865bis of the Luxembourg Civil Code.

 

CHAPTER VII. Applicable Law

 

Article 34. Applicable Law

 

All matters not governed by the Articles of Association shall be determined in accordance with the Laws.

 

 

Moolec Science SA EGM

Sch 1-13

 

 

EX-99.2 3 ea023728901ex99-2_moolec.htm NOTIFICATION RELATED TO THE ADDITION OF AGENDA ITEMS TO THE GENERAL MEETING TO BE HELD ON APRIL 22, 2025

Exhibit 99.2

 

Moolec Science SA

Société anonyme

Registered office: 17, boulevard F.W. Raiffeisen, L-2411 Luxembourg

Grand Duchy of Luxembourg

R.C.S. Luxembourg: B268440

 

 

 

NOTIFICATION RELATED TO THE ADDITION OF AGENTA ITEMS TO

THE GENERAL MEETING TO BE HELD ON 22 APRIL 2025

 

 

 

Following receipt of a request issued in accordance with article 450-8 of the Luxembourg law of 10 August 1915 on commercial companies, as amended, additional items have been added to the agenda of the extraordinary general meeting of shareholders of Moolec Science SA to be held on 22 April 2025, at 1:00 p.m. (Central European Standard Time) at 35, avenue J. F. Kennedy, L-1855 Luxembourg, Grand Duchy of Luxembourg (the “EGM”). Such new items have been added as thirteenth, fourteenth and fifteenth agenda points. All procedures related to attendance, vote and related topics remain unchanged.

 

The thirteenth, fourteenth and fifteenth resolutions related to the added items number thirteenth, fourteenth and fifteenth of the agenda shall be taken at a simple majority of the votes cast by shareholders present or represented.

 

The agenda of the EGM shall therefore read as follows:

 

AGENDA

 

1 After acknowledging that (x) the transfer of the central administration (administration centrale) and registered office (siège social) of the Company from the Grand Duchy of Luxembourg to the Cayman Islands, and the setting of the registered office at c/o Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman KY1-9009, Cayman Islands and the change of nationality of the Company, as approved by the shareholders of the Company during an extraordinary general meeting of the shareholders held in front of a Luxembourg notary on 27 December 2024 are not yet effective since the condition to which the effectiveness of such resolution was subject has not been fulfilled and (y) that as a consequence, the laws applicable to the Company are still the laws of the Grand Duchy of Luxembourg, to approve as a special resolution the amendment and restatement of the Company’s existing amended and restated memorandum and articles (“A&R M&A”) and the adoption of a new set of articles of association in accordance with Luxembourg company laws (the “Articles”), in substitution for and to the entire exclusion of the Company’s A&R M&A, and, as part of such amendment and restatement:

 

(i) to restate its corporate object, so that the corporate object of the Company will read as follows:

 

“The object of the Company is the acquisition, holding and disposal of interests in Luxembourg and/or in foreign companies and undertakings, as well as the administration, development and management of such interests.

 

The Company may provide loans and financing in any other kind or form or grant guarantees or security in any other kind or form, for the benefit of the companies and undertakings forming part of the group of which the Company is a member.

 

1


 

The Company may also invest in real estate, in intellectual property rights or any other movable or immovable assets in any kind or form.

 

The Company may borrow in any kind or form and issue bonds, notes or any other debt instruments as well as warrants or other share subscription rights.

 

In a general fashion, the Company may carry out any commercial, industrial or financial operation, which it may deem useful in the accomplishment and development of its object.”

 

(ii) to acknowledge the report of the board of directors of the Company drawn up in accordance with article 420-26 paragraph (5) sub-paragraph 3 of the Luxembourg law of 10 August 1915 on commercial companies, as amended; and

 

(iii) to approve the creation of an authorised capital in an amount of five billion United States dollars (USD 5,000,000,000.-) divided into five hundred billion (500,000,000,000) shares with a nominal value of one cent (USD 0.01) each, and to give to the board of directors of the Company the authorization to realise increases of the issued share capital of the Company within the limits of the authorised capital of the Company so created and, in particular for that purpose, to determine the time, date, conditions and price of any share issue and to remove or limit the preferential subscription right of the existing shareholders of the Company to any such share issue for a period ending five (5) years after the date of the extraordinary general meeting of shareholders creating an authorised capital.

 

The full text of the special resolution to be voted upon at the EGM excluding the text of the Articles, which is set forth in Schedule 1 hereto and published on the Company website https://ir.moolecscience.com/ is as follows:

 

The general meeting of the shareholders of the Company resolved, as a special resolution to:

 

(i) acknowledge that the transfer of the central administration (administration centrale) and registered office (siège social) of the Company from the Grand Duchy of Luxembourg to the Cayman Islands, and the setting of the registered office at c/o Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman KY1-9009, Cayman Islands and the change of nationality of the Company, as approved by the shareholders of the Company during an extraordinary general meeting of the shareholders held in front of a Luxembourg notary on 27 December 2024 are not yet effective since the condition to which the effectiveness of such resolution was subject has not been fulfilled; that as a consequence, the laws applicable to the Company are still the laws of the Grand Duchy of Luxembourg;

 

(ii) acknowledge the report of the board of directors of the Company drawn up in accordance with article 420-26 paragraph (5) sub-paragraph 3 of the Luxembourg law of 10 August 1915 on commercial companies, as amended;

 

2


 

(iii) create an authorised capital in an amount of five billion United States dollars (USD 5,000,000,000.-) divided into five hundred billion (500,000,000,000) shares with a nominal value of one cent (USD 0.01) each, and to give to the board of directors of the Company the authorization to realise increases of the issued share capital of the Company within the limits of the authorised capital of the Company so created and, in particular for that purpose, to determine the time, date, conditions and price of any share issue and to remove or limit the preferential subscription right of the existing shareholders of the Company to any such share issue for a period ending five (5) years after the date of the extraordinary general meeting of shareholders creating an authorised capital; and

 

(iv) fully amend and restate the A&R M&A in substitution for and to the entire exclusion of the Company’s A&R M&A, including its corporate object with immediate effect and to adopt the Articles set forth in Schedule 1 hereto and, accordingly, the said Articles shall now read as set out in Schedule 1 hereto and as published on the Company website https://ir.moolecscience.com/

 

2 Subject to the adoption of the resolution corresponding to the previous agenda items, to abolish the nominal value of the shares, so that the value of each share will forthwith be its accounting par value as it results from the issued share capital.

 

3 Subject to adoption of the resolutions corresponding to the previous agenda items, to approve the further amendment of the first paragraph of article 5 and the first paragraph of article 6 of the Articles of the Company, in order to reflect the resolution to be adopted under agenda item 2.

 

4 To acknowledge current report on Form 6-K (File No. 001-41586) furnished to the United Stated Securities and Exchange Commission on March 14, 2025, relating to the Nasdaq Staff Determination Letter received by the Company, and to approve, subject to the adoption of the resolutions corresponding to the previous agenda items, a share consolidation of all the shares of the Company, having an accounting par value (the “Existing Shares”), by means of a reverse stock split at a consolidation ratio to be set between 2:1 and 10:1 (the “Consolidation Ratio”) by the board of directors of the Company, and to be implemented by the board of directors of the Company on a date which shall be no later than 6 September 2025 (the “RSS Effective Date”), further subject to approval of the resolutions to be taken on the basis of the below agenda items and to approve the round-up treatment of Existing Shares that cannot be consolidated into a whole number of consolidated shares (the “Share Consolidation”).

 

5 Subject to adoption of the resolutions corresponding to the previous agenda items, to approve the amendment of the first paragraph of article 5 and the first paragraph of article 6 of the Articles of the Company, in order to reflect the consolidation of the Existing Shares pursuant to the Consolidation Ratio.

 

6 Subject to adoption of the resolutions corresponding to the previous agenda items, to delegate all powers to the board of directors of the Company to take all steps required to implement the foregoing resolutions of the shareholders, including to set the Consolidation Ratio, to set the RSS Effective Date, to issue shares under the authorised capital of the Company or to allocate shares held in treasury by the Company, to confirm the amendment of the first paragraph of article 5 and the first paragraph of article 6 of the Articles of the Company, to update the share register of the Company and to do any and all formalities in connection therewith.

 

3


 

7 Subject to adoption of the resolutions corresponding to the previous agenda items, to approve, as described in the prospectus contained in a registration statement (File No. 333-284744) filed with the United States Securities and Exchange Commission, (i) the transfer of the central administration (administration centrale), and registered office (siège social) of the Company by way of continuation from the Grand Duchy of Luxembourg to the Cayman Islands, with continuation of legal personality without interruption or suspension and to designate the registered office at c/o Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman KY1-9009, Cayman Islands (the “Migration”), with effect from the date of issue of a certificate of registration by way of continuation to the Cayman Islands as an exempted company by the Registrar of Companies in the Cayman Islands (the “Effective Date”) and (ii) the continuation of the Company as an exempted company limited by shares in the Cayman Islands, the submission of the Company to the laws of the Cayman Islands and the adoption of the legal form of a Cayman Islands exempted company limited by shares under the laws of the Cayman Islands, each as from the Effective Date.

 

8 Subject to adoption of the resolutions corresponding to the previous agenda items, to approve that the name of the Company shall remain “Moolec Science SA” as from the Effective Date.

 

9 Subject to approval of the Migration, to fully restate the Articles and adopt new memorandum and articles of association (with such variations as required to reflect the Share Consolidation) in substitution for and to the exclusion of, the Company’s existing Articles in order to comply with the laws of the Cayman Islands, as a consequence of the Company becoming a Cayman Islands exempted company limited by shares, as from the Effective Date.

 

The Company’s object shall be changed to “The Company’s objects are unrestricted. As provided by section 7(4) of the Companies Act (Revised), the Company has full power and authority to carry out any object not prohibited by any law of the Cayman Islands”.

 

10 Subject to adoption of the resolutions corresponding to the previous agenda items, to acknowledge the composition of the board of directors of the Company as from the Effective Date will remain as per the composition of the board of directors of the Company as at the date hereof.

 

11 Subject to adoption of the resolutions corresponding to the previous agenda items, to approve that the place where the existing books and records of the Company shall be kept as from the Effective Date shall be c/o Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman KY1-9009, Cayman Islands.

 

12 Subject to adoption of the resolutions corresponding to the previous agenda items, to authorise the board of directors of the Company and each of Linklaters LLP, Ogier (Cayman) LLP and Ogier Global (Cayman) Limited to take all actions required in connection with the Migration, the deregistration of the Company in the Grand Duchy of Luxembourg and the filing of all necessary documents related to the foregoing with the Registrar of Companies in the Cayman Islands.

 

13 To approve the appointment of Diego Nicolás Marcos as director of the Company, with immediate effect and for the period to end following the general meeting which will approve the annual accounts for the period to end on 30 June 2025.

 

4


 

14 To approve the appointment of Oscar Alejandro León Bentancor as director of the Company, with immediate effect and for the period to end following the general meeting which will approve the annual accounts for the period to end on 30 June 2025.

 

15 Subject to adoption of the resolutions corresponding to the agenda items number 13 and 14, to acknowledge the composition of the board of directors of the Company as from the Effective Date will remain as per the composition of the board of directors of the Company as at the date hereof, including following the resolutions taken in accordance with agenda items number 13 and 14.

 

Luxembourg, 7 April 2025

 

The Board of Directors of Moolec Science SA

 

5


 

Schedule 1

 

CHAPTER I. FORM, NAME, REGISTERED OFFICE, OBJECT, DURATION

 

Article 1. Form, Name

 

A société anonyme (the “Company”) is governed by the laws of the Grand Duchy of Luxembourg, in particular the law of 10 August 1915 on commercial companies, as amended (the “Laws”) and by these articles of association (the “Articles of Association”).

 

The Company exists under the name of “Moolec Science SA”.

 

Article 2. Registered Office

 

The Company will have its registered office in the City of Luxembourg.

 

The registered office may be transferred to any other place within the Grand Duchy of Luxembourg by a resolution of the Board of Directors (as defined below). The Board of Directors shall arrange that the Articles of Association are amended to reflect such transfer.

 

Branches or other offices may be established either in the Grand Duchy of Luxembourg or abroad by a resolution of the Board of Directors.

 

In the event that, in the view of the Board of Directors, extraordinary political, economic or social developments occur or are imminent that would interfere with the normal activities of the Company at its registered office or with the ease of communications with this office or between this office and persons abroad, the Company may temporarily transfer the registered office abroad, until the complete cessation of these abnormal circumstances. These temporary measures will have no effect on the nationality of the Company, which, notwithstanding the temporary transfer of the registered office, will remain a company governed by the Laws. These temporary measures will be taken and notified to any interested parties by the Board of Directors.

 

In accordance with the provisions of the Laws, the Company may be converted into a foreign law company without being dissolved or liquidated or put into liquidation and, if applicable, without interruption of its legal personality, provided that the law of the destination country does not oppose such conversion. 

 

Article 3. Object

 

The object of the Company is the acquisition, holding and disposal of interests in Luxembourg and/or in foreign companies and undertakings, as well as the administration, development and management of such interests.

 

The Company may provide loans and financing in any other kind or form or grant guarantees or security in any other kind or form, for the benefit of the companies and undertakings forming part of the group of which the Company is a member.

 

The Company may also invest in real estate, in intellectual property rights or any other movable or immovable assets in any kind or form.

 

The Company may borrow in any kind or form and issue bonds, notes or any other debt instruments as well as warrants or other share subscription rights.

 

In a general fashion, the Company may carry out any commercial, industrial or financial operation, which it may deem useful in the accomplishment and development of its object.

 

 

Moolec Science SA EGM

Sch 1-1

 


 

Article 4. Duration

 

The Company is formed for an unlimited duration.

 

CHAPTER II. CAPITAL, SHARES

 

Article 5. Share Capital

 

The Company’s share capital is set at four hundred one thousand two hundred sixty-eight United States dollars and forty cents (USD 401,268.40), represented by forty million one hundred twenty-six thousand eight hundred forty (40,126,840) shares with a nominal value of one cent (USD 0.01) each (the “Shares”).

 

In addition to the share capital, a premium account may be established to record any premium paid on any Share in addition to its nominal value. The premium account shall constitute a distributable reserve and may notably be used for the payment of the price for any Shares which the Company may repurchase from its shareholder(s), to offset any net realised losses, to make distributions to the shareholder(s) or to allocate funds to the legal reserve.

 

Distributable reserve accounts may be established to record contributions to the Company made by existing shareholders without issuance of Shares. Any such reserve shall constitute a distributable reserve and may notably be used to provide for the payment of the price of any Shares which the Company may repurchase from its shareholder(s), to offset any net realised losses, to make distributions to the shareholder(s) or to allocate funds to the legal reserve.

 

Article 6. Authorised Capital – Free Shares

 

The authorised capital of the Company (excluding the issued share capital) is set at five billion United States dollars (USD 5,000,000,000.-) divided into five hundred billion (500,000,000,000) Shares with a nominal value of one cent (USD 0.01) each.

 

The Board of Directors is authorised, up to the maximum amount of the authorised capital, to (i) increase the issued share capital in one or several tranches with or without share premium, against payment in cash or in kind, by conversion of claims on the Company or in any other manner; (ii) issue subscription and/or conversion rights in relation to new shares or instruments within the limits of the authorised capital under the terms and conditions of warrants (which may be separate or linked to Shares, bonds, notes or similar instruments issued by the Company), convertible bonds, notes or similar instruments; (iii) determine the place and date of the issue or successive issues, the issue price, the terms and conditions of the subscription of and paying up on the new shares and instruments and (iv) remove or limit the statutory preferential subscription right of the shareholders.

 

The Board of Directors may authorise any person to accept on behalf of the Company subscriptions and receive payment for Shares or instruments issued under the authorised capital.

 

The Board of Directors is further authorised to make an allotment of existing or newly issued shares without consideration to the following persons:

 

(a) employees of the Company or certain categories amongst those;

 

(b) employees of companies or economic interest grouping in which the Company holds directly or indirectly at least fifty per cent (50%) of the share capital or voting rights;

 

(c) employees of companies or economic interest grouping in which at least fifty per cent (50%) of the share capital or voting rights is held directly or indirectly by a company which holds directly or indirectly at least fifty per cent (50%) of the share capital of the Company;

 

 

Moolec Science SA EGM

Sch 1-2

 


 

(d) members of the corporate bodies of the Company or of the companies or economic interest grouping listed in point (b) to (c) above or certain categories amongst those.

 

The above authorisations are valid for a period ending five (5) years after the latest of (i) the date of the deed of incorporation of the Company or (ii) the date of the deed enacting the renewal of such authorisations. The above authorisations may be renewed, increased or reduced by a resolution of the General Meeting voting with the quorum and majority rules set for the amendment of the Articles of Association. The shares to be issued upon exercise or conversion of any warrants (which may be separate or linked to Shares, bonds, notes or similar instruments issued by the Company), convertible bonds, notes or similar instruments may be issued beyond the initial authorised capital period of five (5) years as long as such instruments were issued within the relevant initial authorized capital period of five (5) years.

 

Following each increase of the issued share capital in accordance with this Article 6, Article 5 will be amended so as to reflect the capital increase. Any such amendment will be recorded in a notarial deed upon the instructions of the Board of Directors or of any person duly authorised by the Board of Directors for this purpose.

 

Article 7. Increase and Reduction of Capital – Acquisition of own Shares

 

The share capital and/or authorised capital of the Company may be increased or reduced by a resolution of the General Meeting adopted in compliance with the quorum and majority rules set for the amendment of the Articles of Association.

 

The new shares to be subscribed for by contribution in cash will be offered by preference to the existing shareholders in proportion to the part of the capital which those shareholders are holding. The Board of Directors shall determine the period within which the statutory preferential subscription rights (“PSRs”) shall be exercised (the “Subscription Period”) and the PSRs shall be freely negotiable during the Subscription Period. If, at the end of the Subscription Period, not all PSRs have been exercised, the PSRs shall immediately lapse and the Board of Directors may decide that any person (including third parties) may participate in the capital increase by subscribing to the shares which have not been subscribed through the exercise of PSRs during the Subscription Period.

 

Notwithstanding the above, the Board of Directors, within the limit of the authorisation under Article 6 or, the General Meeting, voting in compliance with the quorum and majority rules set for any amendment of the Articles of Association may limit or withdraw the PSRs.

 

The Company may acquire or repurchase Shares.

 

Article 8. Shares

 

8.1 Each Share entitles to one (1) vote.

 

8.2 A shareholder may individually undertake not to exercise, permanently or temporarily, all or part of its voting rights. Such a waiver binds the relevant shareholder and the Company as from its notification to the Company.

 

8.3 The rights and obligations attached to all Shares shall be identical except to the extent otherwise provided by the Articles of Association or by the Laws.

 

8.4 The co-owners of Shares must be represented towards the Company by one (1) joint representative, whether appointed amongst them or not.

 

8.5 The Shares will be in the form of registered shares only.

 

8.6 A register of shares shall be kept by the Company at its registered office, where it shall be available for inspection by any shareholder. This register shall contain the precise designation of each shareholder and the indication of the number of Shares held, the indication of the payments made on the Shares as well as the transfers of Shares and the dates thereof. Ownership of shares will be established by inscription in the said register or in the event separate registrars have been appointed pursuant to Article 8.8, in such separate register(s).

 

 

Moolec Science SA EGM

Sch 1-3

 


 

8.7 The Company may appoint registrars in different jurisdictions who may each maintain a separate register for the Shares entered therein. Shareholders may elect to be entered into one of these registers and to transfer their Shares to another register so maintained. The Board of Directors may however impose transfer restrictions for Shares in compliance with the requirements of the jurisdiction applicable to the Shares at that time. A transfer to the register kept at the Company’s registered office may always be requested.

 

8.8 Subject to the provisions of Articles 8.10 and 8.11, the Company may consider the person in whose name the Shares are registered in the register of shareholders as the full owner of such Shares. In the event that a holder of Shares does not provide an address in writing to which all notices or announcements from the Company may be sent, the Company may permit a notice to this effect to be entered into the register of shareholders and such holder’s address will be deemed to be at the registered office of the Company or such other address as may be so entered by the Company from time to time, until a different address shall be provided to the Company by such holder in writing. The holder may, at any time, change his address as entered in the register of shareholders by means of written notification to the Company.

 

8.9 The Shares may be held by a holder through a securities settlement system or a Depositary (as this term is defined below). The holder of Shares held in such fungible securities accounts has the same rights and obligations as if such holder held the Shares directly. The Shares held through a securities settlement system or a Depositary shall be recorded in an account opened in the name of the holder and may be transferred from one account to another in accordance with customary procedures for the transfer of securities in book-entry form. However, the Company will make dividend payments, if any, and any other payments in cash, shares or other securities, if any, only to the securities settlement system or Depositary recorded in the register of shareholders or in accordance with the instructions of such securities settlement system or Depositary. Such payment will grant full discharge of the Company’s obligations in this respect.

 

8.10 All communications and notices to be given to a registered shareholder shall be deemed validly made if made to the latest address communicated by the shareholder to the Company in accordance with Article 8.8 or, if no address has been communicated by the shareholder, the registered office of the Company or such other address as may be so entered by the Company in the register from time to time according to Article 8.8.

 

8.11 Where Shares are recorded in the register of shareholders in the name of or on behalf of a securities settlement system or the operator of such system and recorded as book-entry interests in the accounts of a professional depositary or any sub-depositary (any depositary and any sub-depositary being referred to as a “Depositary”), the Company – subject to having received from the Depositary a certificate (or such other document as accepted by the Company) in proper form – will permit the Depositary of such book-entry interests to exercise the rights attaching to the Shares corresponding to the book-entry interests of the relevant holder, including receiving notices of general meetings, admission to and voting at general meetings, and shall consider the Depositary to be the holder of the Shares corresponding to the book-entry interests for purposes of this Article 8 of the present Articles of Association. The Board of Directors may determine the formal requirements with which such certificates (or such other document as accepted by the Company) must comply and the exercise of the rights in respect of such Shares may in addition be subject to the internal rules and procedures of the securities settlement system.

 

 

Moolec Science SA EGM

Sch 1-4

 


 

8.12 Any person who is required to report ownership of Shares on Schedule 13D or 13G pursuant to Rule 13d-1 or changes in such ownership pursuant to Rule 13d-2, each as promulgated by the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, must notify the Company’s Board of Directors promptly following any reportable acquisition or disposition, and in no event later than the filing date of such Schedule 13D or 13G, of the proportion of Shares held by the relevant person as a result of the acquisition or disposal.

 

Article 9. Transfer of Shares

 

The Shares are freely transferable in accordance with the provisions of the Law, subject to any contractual restrictions or restrictions on transfer under applicable securities laws of any jurisdiction to which the Shares are subject.

 

Without prejudice to the conditions for transfer by book entries provided for in Article 8.10 of these Articles of Association, any transfer of Shares will be registered in the register of shares by a declaration of transfer entered into the register of shares, dated and signed by the transferor and the transferee or by their representative(s) as well as in accordance with the rules on the transfer of claims laid down in article 1690 of the Luxembourg Civil Code. Furthermore, the Company may accept and enter into the register of shares any transfer referred to in any correspondence or other document recording the consent of the transferor and the transferee.

 

Ownership of a Share carries implicit acceptance of the Articles of Association and of the resolutions validly adopted by the General Meeting.

 

A transfer of Shares in breach of provisions of the Articles of Association shall be null and void.

 

Article 10. Incapacity, Death, Suspension of Civil Rights, Bankruptcy or Insolvency of a shareholder

 

The incapacity, death, suspension of civil rights, bankruptcy, insolvency, liquidation, or any other similar event affecting one or more shareholder(s) does not put the Company into liquidation.

 

CHAPTER III. BOARD OF DIRECTORS, AUDITORS

 

Article 11. Board of Directors

 

The Company shall be managed by a board of directors (the “Board of Directors”).

 

The Board of Directors shall be composed of not less than five (5) members (the “Directors”), who may but do not need to be shareholders of the Company themselves.

 

If and as long as the Company has only one (1) shareholder, the Board of Directors may comprise one (1) Director only.

 

Each Director will be appointed by the General Meeting by a simple majority of votes cast. The General Meeting shall determine the number of Directors and the duration of their mandate. The resolutions of the General Meeting approving the appointment of a Director shall require a separate vote for each individual candidate Director.

 

 

Moolec Science SA EGM

Sch 1-5

 


 

The duration of the mandate of any Directors appointed shall be determined so as not to exceed the date of the annual general meeting of shareholders of the Company approving the annual accounts of the next financial year following their appointment.

 

Each Director is eligible for re-appointment for successive terms and may be removed at any time, with or without cause by a resolution of the General Meeting.

 

In the event of a vacancy on the Board of Directors, the remaining Directors may elect by co-optation a new Director to fill such vacancy until the next General Meeting, which shall ratify such co-optation or elect a new Director instead.

 

Article 12. Powers of the Board of Directors

 

The Board of Directors is vested with the broadest powers to perform all acts necessary or useful to accomplish the Company’s object.

 

All powers not expressly reserved by the Articles of Association or by the Laws to the General Meeting or to the Auditor(s) (as defined below) shall be within the competence of the Board of Directors.

 

Article 13. Delegation of Powers - Representation of the Company

 

The Board of Directors may delegate the daily management of the Company and the representation of the Company for that daily management to one or more persons or committees of its choice.

 

The Board of Directors may create one or several committees. The composition and the powers of such committee(s), the terms of the appointment, removal, remuneration and duration of the mandate of its/their members, as well as its/their rules of procedure are determined by the Board of Directors. The Board of Directors shall be in charge of the supervision of the activities of the committee(s).

 

The Board of Directors may also grant other special powers of attorney or entrust permanent or temporary tasks to one or more persons of its choice. Such persons shall exercise the tasks entrusted to them under the supervision of the Board of Directors.

 

The remuneration and other benefits granted to the person(s) to whom the daily management has been delegated must be reported annually by the Board of Directors to the General Meeting.

 

The Company will be bound towards third parties by the individual signature of the sole Director or by the joint signatures of any three (3) Directors.

 

The Company will further be bound towards third parties by the joint signatures or single signature of any person(s) to whom the daily management of the Company has been delegated, for that daily management, or by the joint signatures or sole signature of any person(s) to whom any special power of attorney has been granted, but only within the limits of that special power of attorney.

 

Article 14. Meetings of the Board of Directors

 

The Board of Directors may appoint from among its members a chairperson (the “Chairperson”).

 

The Board of Directors will meet upon call by the Chairperson or by any Director in accordance with the provisions of this Article 14.

 

The Chairperson will preside over all meetings of the Board of Directors, except that in the absence of the Chairperson, the Board of Directors may appoint another Director as chairperson for the relevant meeting by a majority of the votes of the Directors present or represented at such meeting.

 

 

Moolec Science SA EGM

Sch 1-6

 


 

Except in case of urgency or with the prior consent of all those entitled to attend, which consent shall be recorded in the minutes of the meeting at least forty-eight (48) hours’ written notice of meetings of the Board of Directors shall be given in writing and transmitted by any means of communication allowing for the transmission of a written text. Any such notice shall specify the time and the place of the meeting, as well as the agenda and the nature of the business to be resolved upon. The notice may be waived by properly documented consent of each Director which consent shall be recorded in the minutes of the meeting. No separate notice is required for meetings held at times and places specified in a time schedule previously adopted by resolution of the Board of Directors.

 

The meetings of the Board of Directors shall be held in the Grand Duchy of Luxembourg or at such other place as the Board of Directors may from time to time determine.

 

Any Director may be represented at any meeting of the Board of Directors by appointing in writing, transmitted by any means of communication allowing for the transmission of a written text, another Director as his proxy. Any Director may represent one or more Directors.

 

The quorum for a valid meeting of the Board of Directors shall be the presence or the representation of at least half (1/2) of the Directors.

 

When the rules of a foreign stock exchange require that, at least once a year, only independent directors of the Company may hold a meeting of the Board of Directors, the quorum required for a meeting of the Board of Directors can be disregarded and the independent directors must all be present or represented at such meeting. The independent directors may appoint a chairman pro tempore at such meetings.

 

Resolutions of the Board of Directors in a meeting will be taken by a majority of the votes of the Directors present or represented at such meeting. The Chairperson shall have no casting vote in case of a tie.

 

Directors may participate in a meeting by conference call, videoconference or any other similar means of communication enabling thus several persons participating therein to simultaneously communicate with each other on a continuous basis. A meeting held using such means of communication is deemed to have taken place at the Company’s registered office.

 

A written resolution, signed by all the Directors and transmitted by any means of communication allowing for the transmission of a written text, is proper and valid as though it had been adopted at a meeting of the Board of Directors which was duly convened and held. Such a resolution may be documented in a single document or in several separate documents having the same content and each of them signed by one or several Directors. A written resolution passed in this way is deemed to have been taken at the Company’s registered office.

 

Article 15. Resolutions of the Board of Directors

 

The resolutions of the Board of Directors shall be recorded in writing.

 

The minutes of any meeting of the Board of Directors will be signed by the Chairperson or the chairperson of the meeting or by any three (3) Directors.

 

Copies or extracts of written resolutions or minutes, to be produced in judicial proceedings or otherwise, may be signed by the sole Director or by any three (3) Directors acting jointly.

 

In case of a sole Director, resolutions shall be documented in writing and signed by the sole Director.

 

 

Moolec Science SA EGM

Sch 1-7

 


  

Article 16. Management Fees and Expenses

 

Subject to approval by the General Meeting, Directors may receive a management fee for their management of the Company and may, in addition, be reimbursed for all other expenses whatsoever incurred by the relevant Director in relation to the management of the Company.

 

Article 17. Conflicts of Interest

 

If any Director has or may have a direct or indirect financial interest in any transaction which requires the approval of the Board of Director(s), that Director shall disclose that interest to the Board of Directors and shall not take part of any deliberation or vote on any such transaction.

 

Such transaction and such Director’s interest shall be disclosed in a special report to the next General Meeting before any resolution is passed.

 

In case of a sole Director, record is kept in writing of the transactions where the sole Director has such direct or indirect financial interest.

 

Where, due to a conflict of interests, the number of Directors required to be present or represented for a valid quorum is not reached, the Board of Directors may defer the decision to the General Meeting.

 

The foregoing paragraphs do not apply if the relevant transaction falls within the ordinary course of business of the Company and is entered into at arm’s length under market conditions.

 

No transaction between the Company and any other party shall be affected or invalidated by the mere fact that a Director (or any one of its directors, managers, officers or employees) is a director, manager, associate, member, shareholder, officer or employee of that other party. Any person related as described above to any company or firm with which the Company shall contract or otherwise engage in business shall not, by reason of such affiliation, be automatically prevented from considering, voting or acting upon any matters with respect to such contract or other business.

 

The provisions of this article apply mutatis mutandis to the persons to whom the Board of Directors has delegated the daily management of the Company, except that in case the Board of Directors has delegated the daily management of the Company to a single person, the decision shall be deferred to the Board of Directors.

 

Article 18. Directors’ Liability; Indemnification

 

Directors are not held personally liable for the indebtedness or other obligations of the Company. As agents of the Company, they are responsible for the performance of their duties. Subject to the exceptions and limitations listed in below and mandatory provisions of law, every person who is, or has been, a Director or officer of the Company (and his or her heirs, executors and administrators) shall be indemnified by the Company to the fullest extent permitted by law against liability and against all expenses reasonably incurred or paid by such person in connection with any claim, action, suit or proceeding which he becomes involved as a party or otherwise by virtue of his or her being or having been a director or officer of the Company, or, at the request of the Company, of any other company of which the Company is a shareholder or creditor and by which he is not entitled to be indemnified, and against amounts paid or incurred by him or her in the settlement thereof. The words “claim”, “action”, “suit” or “proceeding” shall apply to all claims, actions, suits or proceedings (civil, criminal or otherwise including appeals) actual or threatened and the words “liability” and “expenses” shall include without limitation attorneys’ fees, costs, judgments, amounts paid in settlement and other liabilities.

 

 

Moolec Science SA EGM

Sch 1-8

 


  

No indemnification shall be provided to any Director, officer or shareholder (i) against any liability by reason of willful misfeasance, bad faith, gross negligence or reckless disregard of the duties involved in the conduct of his or her office, (ii) with respect to any matter as to which he or she shall have been finally adjudicated to have acted in bad faith and not in the interest of the Company or (iii) in the event of a settlement, unless the settlement has been approved by a court of competent jurisdiction or by the Board of Directors.

 

The right of indemnification herein provided shall be severable, shall not affect any other rights to which any director or officer may now or hereafter be entitled, shall continue as to a person who has ceased to be such director or officer and shall inure to the benefit of the heirs, executors and administrators of such a person. Nothing contained herein shall affect or limit any rights to indemnification to which corporate personnel, including directors and officers, may be entitled by contract or otherwise under law. The Company shall specifically be entitled to provide contractual indemnification to and may purchase and maintain insurance for any corporate personnel, including directors and officers of the Company, as the Company may decide upon from time to time.

 

Article 19. Confidentiality

 

Even after cessation of their mandate or function, any Director, as well as any person who is invited to attend a meeting of the Board of Directors, shall not disclose information on the Company, the disclosure of which may have adverse consequences for the Company, unless such divulgation is required (i) by a legal or regulatory provision applicable to sociétés anonymes or (ii) for the public benefit.

 

Article 20. Auditors

 

The auditing of the Company may be entrusted to one or several auditors (commissaires) (the “Auditors”).

 

When so required by the Laws, the auditing of the Company must be entrusted to one or several approved statutory auditors (réviseurs d’entreprises agréés) (“Réviseurs”). When a Réviseur is appointed, no Auditor needs to be appointed.

 

The Auditors or Réviseurs, if any, will be appointed by the General Meeting, which will determine the number of Auditors or Réviseurs and the duration of their mandate. Each of them is eligible for re-appointment. Unless otherwise provided by the Laws, they may be removed at any time, with or without cause, by a resolution of the General Meeting.

 

CHAPTER IV. GENERAL MEETING

 

Article 21. Powers of the General Meeting

 

The general meeting of shareholders (the “General Meeting”) shall have such powers as are vested in it pursuant to the Articles of Association and the Laws.

 

Article 22. Annual General Meeting

 

An annual General Meeting shall be held in the Grand Duchy of Luxembourg within six (6) months of the end of the preceding financial year, except for the first annual General Meeting which may be held within eighteen (18) months from incorporation.

 

Article 23. Other General Meetings

 

The Board of Directors or the Auditor(s) (if any) may convene General Meetings (in addition to the annual General Meeting). Such meetings must be convened if shareholders representing at least ten per cent (10%) of the Company’s share capital so require.

 

General Meetings, including the annual General Meeting, will be held at the registered office of the Company or at such other place in the Grand Duchy of Luxembourg, and may be held abroad if, in the judgement of the Board of Directors, circumstances of force majeure so require.

 

 

Moolec Science SA EGM

Sch 1-9

 


  

Article 24. Notice of General Meetings

 

The shareholders shall meet in a General Meeting upon issuance of a convening notice in accordance with the Laws which shall specify the time and the place of the General Meeting as well as the agenda and the nature of the business to be resolved upon at the relevant General Meeting. The agenda for a General Meeting shall also describe any proposed changes to the Articles of Association and, if applicable, set out the text of those changes affecting the object or form of the Company. If the Shares are listed on a foreign stock exchange, the requirements of such foreign stock exchange applicable to the Company shall additionally be complied with.

 

If the Shares are listed on a foreign stock exchange, all shareholders of the Company (for the avoidance of doubt, including any registered shareholder, any Depositary and, without prejudice to any requirements as set out in any other provision of these Articles of Association, any holder of Shares) are entitled to be admitted to any General Meeting, provided, however, that the Board of Directors may determine a date and time preceding the General Meeting as the record date for admission to such meeting, which may not be less than five (5) calendar days before the date of such meeting (the “Record Date”).

 

Shareholders holding individually or collectively at least ten (10) per cent of the issued share capital of the Company, may request the addition of one or several new items on the agenda of the General Meeting. This right shall be exercised upon request of the shareholders in writing submitted to the Company by registered letter at the address of the registered office of the Company. The requests shall include the details requested in the convening notice. The requests from the shareholders shall be received by the Company no later than five (5) calendar days before the General Meeting.

 

Article 25. Attendance - Representation

 

Each shareholder is entitled to attend and speak at any General Meeting.

 

A shareholder may be represented at any General Meeting by another person (who does not need to be a shareholder) appointed in writing (transmitted by any means of communication allowing for the transmission of a written text) as a proxyholder by the shareholder. A proxyholder may represent more than one (1) shareholder.

 

Shareholders taking part in a meeting by conference call, through video conference or by any other means of communication allowing for their identification, allowing all persons taking part in the meeting to hear one another on a continuous basis and allowing for an effective participation of all such persons in the meeting, are deemed to be present for the computation of the quorums and votes, subject to such means of communication being made available at the place of the meeting. A General Meeting held in this way is deemed to have taken place at the Company’s registered office.

 

Article 26. Proceedings

 

Any General Meeting shall be presided over by the Chairperson or, in the absence of the Chairperson, by a person designated by the Board of Directors or, in the absence of such designation, by a resolution of the General Meeting.

 

The chairperson of the General Meeting shall appoint a secretary.

 

By resolution of the General Meeting one (1) scrutineer shall be appointed from the persons attending the General Meeting.

 

The chairperson, the secretary and the scrutineer together form the board of the relevant General Meeting.

 

 

Moolec Science SA EGM

Sch 1-10

 


  

In connection with each General Meeting, the Board of Directors is authorised to provide such rules of deliberations and such conditions for allowing shareholders to take part in the meeting as the Board of Directors deems appropriate.

 

Except to the extent inconsistent with the rules and conditions as adopted by the Board of Directors, the person presiding over the General Meeting shall have the power and authority to prescribe such additional rules and conditions and to do all such acts as, in the judgment of such person, are appropriate for the proper conduct of the meeting. Such rules and conditions, whether adopted by the Board of Directors or prescribed by the person presiding over the meeting, may include, in each case to the extent permitted by applicable law:

 

(a) determining the order of business for the meeting;

 

(b) rules and procedures for maintaining order at the meeting and the safety of those present;

 

(c) limitations on attendance at or participation in the meeting to shareholders of record, their duly authorised and constituted attorneys or such other persons as the person presiding over the meeting shall determine;

 

(d) restrictions on entry to the meeting after the time fixed for the commencement thereof; and

 

(e) limitations on the time allotted to questions or comments by participants.

 

Article 27. Adjournment

 

Without limiting the generality of Article 26 and irrespective of the agenda, the Board of Directors may adjourn any General Meeting in accordance with the formalities and time limits stipulated for by the Law.

 

Such adjournment automatically cancels any resolution already adopted prior thereto.

 

The adjourned General Meeting has the same agenda as the first one. Shares and proxies regularly deposited in view of the first meeting remain validly deposited for the second one.

 

Article 28. Voting at General Meetings

 

An attendance list indicating the name of each shareholder and the number of Shares for which he votes is signed by or on behalf of each shareholder present or represented by proxy, prior to the start of the General Meeting.

 

The Board of Directors may in its sole discretion authorize each shareholder to vote at a General Meeting through a signed voting form sent by post, electronic mail, facsimile or any other means of communication to the Company’s registered office or to the address specified in the convening notice. Subject to such authorisation by the Board of Directors, the shareholders may only use voting forms provided by the Company which contain at least the date, place and time of the meeting, the agenda of the meeting and the text of the proposed resolutions. For each resolution, the form must contain three boxes allowing the shareholder to vote in favor thereof, against, or abstain from voting by ticking the appropriate box. For the avoidance of doubt, shareholders may not vote by voting forms where the Board of Directors has not authorised such voting method for a given General Meeting.

 

Voting forms which, for a proposed resolution, do not show (i) a vote in favor of the proposed resolution, (ii) a vote against the proposed resolution or (iii) an abstention from voting on the proposed resolution, are void with respect to such resolution. If a shareholder votes by means of a voting form, the voting form shall be deposited at the registered office of the Company or with an agent of the Company duly authorised to receive such voting forms. The Company shall only take into account voting forms received no later than three (3) business days prior to the date of the General Meeting to which they relate. The Board of Directors may set a shorter period for the submission of the voting forms.

 

 

Moolec Science SA EGM

Sch 1-11

 


  

If a shareholder votes by means of proxy, the proxy shall be deposited at the registered office of the Company or with an agent of the Company duly authorised to receive such proxies. The Company shall only take into account proxies received no later than three (3) business days prior to the date of the General Meeting to which they relate. The Board of Directors may set a shorter period for the submission of the proxies.

 

A holder of Shares held through the operator of a securities settlement system or with a Depositary wishing to attend a General Meeting must provide the Company with a certificate issued by such operator or Depositary certifying the number of Shares recorded in the relevant account on the Record Date. Such certificate must be provided to the Company no later than three (3) business days prior to the date of such general meeting. If such holder of shares votes by means of a proxy, Article 28 of these Articles of Association shall apply.

 

Resolutions the adoption of which is not subject to the quorum and the majority requirements for an amendment of the Articles of Association, shall be adopted, irrespective of the number of Shares represented, by a simple majority of votes cast.

 

For resolutions the adoption of which is subject to the quorum and majority requirements for an amendment of the Articles of Association, the quorum shall be at least one half (1/2) of all the Shares issued and outstanding and the resolutions shall be adopted by a two thirds (2/3rds) majority of the votes cast. If the said quorum is not reached at a first meeting, a second meeting may be convened and resolutions shall be adopted, irrespective of the number of Shares represented, by a two thirds (2/3rds) majority of the votes cast.

 

The resolutions of the General Meeting approving the appointment of a Director shall require a separate vote for each individual candidate Director.

 

Article 29. Minutes

 

The minutes of a General Meeting shall be signed by the members of the board of that General Meeting and may be signed by or on behalf of any shareholders, who so request.

 

CHAPTER V. FINANCIAL YEAR, FINANCIAL STATEMENTS, DISTRIBUTION OF PROFITS

 

Article 30. Financial Year

 

The Company’s financial year begins on the first day of July and ends on the last day of June of each calendar year.

 

Article 31. Adoption of Financial Statements

 

After the end of each financial year, the Board of Directors draws up the annual financial statements of the Company in accordance with the Laws.

 

The annual statutory and/or consolidated financial statements are submitted to the General Meeting for approval.

 

Each shareholder or his representative may also peruse the financial statements of the Company at the registered office of the Company.

 

 

Moolec Science SA EGM

Sch 1-12

 


 

Article 32. Distribution of Profits

 

From the annual net profits of the Company, at least five per cent (5%) shall each year be allocated to the reserve required by Laws (the “Legal Reserve”). That allocation to the Legal Reserve will cease to be required as soon and as long as the Legal Reserve amounts to ten per cent (10%) of the amount of the share capital of the Company.

 

The General Meeting shall resolve how the remainder of the annual net profits, after allocation to the Legal Reserve in accordance with the previous paragraph, will be disposed of by allocating the whole or part of the remainder to a reserve or to a provision, by carrying it forward to the next following financial year or by distributing it, together with carried forward profits, distributable reserves or share premium to the shareholder(s), each Share entitling to the same proportion in such distributions.

 

Subject to the provisions of the Laws and in compliance with the provisions in the previous two paragraphs, the Board of Directors may resolve that the Company pays out an interim dividend to the shareholders. The Board of Directors shall set the amount and the date of payment of the interim dividend.

 

Any share premium, assimilated premium or other distributable reserve may be freely distributed to the shareholders subject to the provisions of the Law and the Articles of Association.

 

CHAPTER VI. DISSOLUTION, LIQUIDATION

 

Article 33. Dissolution, Liquidation

 

The Company may be dissolved by a resolution of the General Meeting adopted in compliance with the quorum and majority rules set for any amendment of the Articles of Association.

 

Should the Company be dissolved, the liquidation will be carried out by the Board of Directors or such other person(s) (who may be physical persons or legal entities) appointed by the General Meeting. The General Meeting shall also determine the powers and the compensation (if any) of such other person(s).

 

After settlement of all the debts and liabilities of the Company, including the expenses of liquidation, the net liquidation proceeds shall be distributed to the shareholder(s) in compliance with the same preference as set out for dividend distributions.

 

In case the Company has only one (1) shareholder, it may also be dissolved without liquidation in accordance with article 1865bis of the Luxembourg Civil Code.

 

CHAPTER VII. Applicable Law

 

Article 34. Applicable Law

 

All matters not governed by the Articles of Association shall be determined in accordance with the Laws.

 

 

Moolec Science SA EGM

Sch 1-13